Nexalin Technology (NXL) vs Profusa (PFSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nexalin Technology is the larger company by market cap ($3.0 million vs $860,018), about 3.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NXL | PFSA |
|---|---|---|
| Share price | $3.63 | $1.42 |
| Market cap | $3.01M | $860.02K |
| 1-day change | -11.68% | -4.70% |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-14.10 | $897.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.70 | $3,000.00 |
| 52-week low | $3.50 | $1.40 |
| Distance from 52-week high | -92.84% | -99.95% |
| Analyst consensus | buy | — |
| Avg. price target upside | +313.22% | — |
| Average volume | 1.02M | 2.74M |
| Shares outstanding | 829.40K | 605.65K |
| Employees | 8 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nexalin Technology is about 3.5 times larger than Profusa by market value ($3.01M vs $860.02K).
About Nexalin Technology
NXL stock →Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 8 employees
About Profusa
PFSA stock →Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery.
Health Care · Medical/Dental Instruments
NXL vs PFSA FAQ
Which is bigger, Nexalin Technology or Profusa?
Nexalin Technology (NXL) is larger, with a market capitalization of $3.01M compared with $860.02K for Profusa (PFSA).
Are Nexalin Technology and Profusa in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Electromedical & Electrotherapeutic Apparatus for Nexalin Technology and Medical/Dental Instruments for Profusa.